BriaCell Therapeutics (NASDAQ:BCTX) Price Target Raised to $32.00

BriaCell Therapeutics (NASDAQ:BCTX) had its price objective increased by HC Wainwright from $15.00 to $32.00 in a research report sent to investors on Monday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for BriaCell Therapeutics’ Q2 2025 earnings at ($1.94) EPS, Q3 2025 earnings at ($1.12) EPS, Q4 2025 earnings at ($1.14) EPS, FY2025 earnings at ($2.45) EPS, FY2026 earnings at ($1.47) EPS, FY2027 earnings at ($1.09) EPS, FY2028 earnings at ($0.69) EPS and FY2029 earnings at ($0.24) EPS.

BriaCell Therapeutics Trading Up 9.3 %

Shares of BCTX opened at $4.48 on Monday. BriaCell Therapeutics has a 12-month low of $3.92 and a 12-month high of $65.25. The firm has a market capitalization of $13.22 million, a P/E ratio of -0.34 and a beta of 1.59. The firm has a 50-day moving average price of $8.79 and a 200 day moving average price of $10.33.

BriaCell Therapeutics (NASDAQ:BCTX) last posted its quarterly earnings results on Monday, December 16th. The company reported ($3.30) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($2.10). Equities research analysts predict that BriaCell Therapeutics will post -15.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BriaCell Therapeutics

An institutional investor recently raised its position in BriaCell Therapeutics stock. Vontobel Holding Ltd. raised its position in shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX) by 37.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 110,000 shares of the company’s stock after buying an additional 30,000 shares during the period. Vontobel Holding Ltd. owned about 0.25% of BriaCell Therapeutics worth $62,000 as of its most recent filing with the Securities & Exchange Commission. 15.42% of the stock is owned by hedge funds and other institutional investors.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.